{"nctId":"NCT01472822","briefTitle":"Efficacy of Omija (Schisandra Chinensis) Extract in Subjects With Knee Osteoarthritis","startDateStruct":{"date":"2011-03"},"conditions":["Mild Knee Osteoarthritis"],"count":60,"armGroups":[{"label":"Omija extract.","type":"EXPERIMENTAL","interventionNames":["Dietary Supplement: Omija extract."]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Dietary Supplement: Placebo"]}],"interventions":[{"name":"Omija extract.","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females 30-70 years old\n* mild to Moderate KO(Knee Osteoarthritis) as indicated by WOMAC(Western Ontario and McMaster University Osteoarthritis Index) score â‰¥ 38\n* Able to walk\n* Subject agrees not to start any new therapies for OA during the course of the study\n* Able to give informed consent\n\nExclusion Criteria:\n\n* History of underlying inflammatory arthropathy; septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; ochronosis; haemochromatosis; heritable arthritic disorder or collagen gene mutations or rheumatoid arthritis\n* Expectation of surgery in the next 4 months\n* Recent injury in the area affected by OA of the knee, i.e. meniscal tear (past 4 months)\n* Cartilage reconstruction procedure in the target knee\n* Intra-articular corticosteroid injections in the target knee within the last 3 months\n* Viscous injections in the target knee within the last 6 months\n* Abnormal liver or kidney function tests (ALT or AST \\> 2 times the upper limit of normal; elevated creatinine, males\\>125 umol/L, females\\>110 umol/L)","healthyVolunteers":true,"sex":"ALL","minimumAge":"30 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Changes in WOMAC (Western Ontario and McMaster University Osteoarthritis Index) Totol Score","description":"WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score (score 0-96) was measured in study visit 1(0 week) and visit 3(12 week).\n\nThe original index consists of 24 Questions. Individual question response is assigned a score of between 0 (none) to 4 (extreme) and summed to form a score ranging from 0 (best) to 96 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":"11.6"},{"groupId":"OG001","value":"53.3","spread":"11.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":"17.2"},{"groupId":"OG001","value":"31.5","spread":"15.5"}]}]}]},{"type":"SECONDARY","title":"Changes in Lysholm Index Score","description":"Lysholm index score total score (score 0-100) was measured in study visit 1(0 week) and visit 3(12 week).\n\nThe original index consists of 9 Questions(Limp, Assive devices, Up stair, Giving way, Sauat, Sit down\\&up, Cripitation, Swelling, Pain). Lysholm index score total score summed to form a score ranging from 0 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":"11.0"},{"groupId":"OG001","value":"48.3","spread":"13.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.8","spread":"10.8"},{"groupId":"OG001","value":"59.9","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"Changes in Hs-CRP(High Sensitivity C-reactive Protein)","description":"hs-CRP(high sensitivity C-reactive protein) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.4"},{"groupId":"OG001","value":"1.2","spread":"4.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.9"},{"groupId":"OG001","value":"0.6","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Changes in OSC(Osteocalcin)","description":"OSC(Osteocalcin) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"6.2"},{"groupId":"OG001","value":"16.6","spread":"7.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"5.3"},{"groupId":"OG001","value":"17.3","spread":"7.4"}]}]}]},{"type":"SECONDARY","title":"Changes in DPD(Deoxypyridinoline)","description":"DPD(Deoxypyridinoline) was measured in study visit 1(0 week) and visit 3(12 week).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"2.5"},{"groupId":"OG001","value":"7.2","spread":"2.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"1.9"},{"groupId":"OG001","value":"7.5","spread":"2.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":[]}}}